Commentary
This article summarizes the (mainly preclinical) evidence of the role of adipose tissue inflammation and NAFLD via macrophages that play an important role in connecting adipose tissue inflammation to liver inflammation (the adipose tissue-liver) axis. It concludes that macrophage targeting has potential as a therapeutic strategy in metabolic disease and that we may see advances in the future.
Previous Post
Experts perspective - Liver meeting 2019 - Boston
Next Post
Non-alcoholic fatty liver disease in non-obese individuals: Prevalence, pathogenesis and treatment